Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Experimental Cutaneous Candidiasis in Rodents-Reply

Experimental Cutaneous Candidiasis in Rodents-Reply Abstract In Reply.— Dr Gammon raises an important issue that is central to our argument in support of a complement-mediated inflammatory response to Candida sp. Our studies do presume that neutrophils from CoF-treated and/or C5-deficient animals are chemotactically responsive and are not "deactivated" as he proposes. This presumption is based on the following studies: (1) CoF, administered intravenously in rabbits, has no effect 24 hours later on in vitro chemotaxis of peritoneal neutrophils. Furthermore, peripheral neutrophil properties of immune adherence to, and phagocytosis of, C3-bound particles remain normal.1 (2) Rats that are depleted of complement by aggregated human γ-globulin or zymosan exhibit normal polymorphonuclear neutrophil (PMN) chemotaxis and phagocytosis.2 (3) Dr Gammon is correct in assuming that leukocyte responsiveness to chemotactins is intact in C5-deficient mice. Peripheral PMNs from C5-deficient (B10D2/old line) mice respond equally, as well as PMNs from C5-sufficient (B10D2 References 1. Cochrane CG, Müller-Eberhard HJ, Aikin BS: Depletion of plasma complement in vivo by a protein of cobra venom: Its effect on various immunologic reactions . J Immunol 105:55-59, 1970. 2. Ward PA, Cochrane CG: Bound complement and immunologic injury of blood vessels . J Exp Med 121:215-233, 1965.Crossref 3. Snyderman R, Phillips JK, Mergenhagen SE: Biological activity of complement in vivo: Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates . J Exp Med 134:1131-1143, 1971.Crossref 4. Alper CA, Balavitch D: Cobra venom factor: Evidence for its being altered cobra C3 (the third component of complement) . Science 191:1276-1277, 1976.Crossref 5. Fernandez HN, Henson PM, Otani A, et al: Chemotactic response to human C3a and C5a anaphylatoxins: I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions . J Immunol 120:109-115, 1978. 6. O'Flaherty JT, Showell HJ, Ward PA: Neutropenia induced by systemic infusion of chemotactic factors . J Immunol 118:1586-1589, 1977. 7. O'Flaherty JT, Kreutzer DL, Ward PA: Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes . Am J Pathol 90:537-550, 1978. 8. Cutler JE: Chemotactic factor produced by Candida albicans . Infect Immun 18:568-573, 1977. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Experimental Cutaneous Candidiasis in Rodents-Reply

Archives of Dermatology , Volume 115 (1) – Jan 1, 1979

Loading next page...
 
/lp/american-medical-association/experimental-cutaneous-candidiasis-in-rodents-reply-XLRpFicIEA
Publisher
American Medical Association
Copyright
Copyright © 1979 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1979.04010010073031
Publisher site
See Article on Publisher Site

Abstract

Abstract In Reply.— Dr Gammon raises an important issue that is central to our argument in support of a complement-mediated inflammatory response to Candida sp. Our studies do presume that neutrophils from CoF-treated and/or C5-deficient animals are chemotactically responsive and are not "deactivated" as he proposes. This presumption is based on the following studies: (1) CoF, administered intravenously in rabbits, has no effect 24 hours later on in vitro chemotaxis of peritoneal neutrophils. Furthermore, peripheral neutrophil properties of immune adherence to, and phagocytosis of, C3-bound particles remain normal.1 (2) Rats that are depleted of complement by aggregated human γ-globulin or zymosan exhibit normal polymorphonuclear neutrophil (PMN) chemotaxis and phagocytosis.2 (3) Dr Gammon is correct in assuming that leukocyte responsiveness to chemotactins is intact in C5-deficient mice. Peripheral PMNs from C5-deficient (B10D2/old line) mice respond equally, as well as PMNs from C5-sufficient (B10D2 References 1. Cochrane CG, Müller-Eberhard HJ, Aikin BS: Depletion of plasma complement in vivo by a protein of cobra venom: Its effect on various immunologic reactions . J Immunol 105:55-59, 1970. 2. Ward PA, Cochrane CG: Bound complement and immunologic injury of blood vessels . J Exp Med 121:215-233, 1965.Crossref 3. Snyderman R, Phillips JK, Mergenhagen SE: Biological activity of complement in vivo: Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates . J Exp Med 134:1131-1143, 1971.Crossref 4. Alper CA, Balavitch D: Cobra venom factor: Evidence for its being altered cobra C3 (the third component of complement) . Science 191:1276-1277, 1976.Crossref 5. Fernandez HN, Henson PM, Otani A, et al: Chemotactic response to human C3a and C5a anaphylatoxins: I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions . J Immunol 120:109-115, 1978. 6. O'Flaherty JT, Showell HJ, Ward PA: Neutropenia induced by systemic infusion of chemotactic factors . J Immunol 118:1586-1589, 1977. 7. O'Flaherty JT, Kreutzer DL, Ward PA: Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes . Am J Pathol 90:537-550, 1978. 8. Cutler JE: Chemotactic factor produced by Candida albicans . Infect Immun 18:568-573, 1977.

Journal

Archives of DermatologyAmerican Medical Association

Published: Jan 1, 1979

References